Antibe Therapeutics Inc

GoodCap Pharmaceuticals, co-founded by a molecular biologist and innovative entrepreneurs, is dedicated to improving the lives of individuals suffering from neuroinflammatory diseases through the development of more effective and safer medicines. Their lead drug candidate, GCAP001, combines two classes of molecules in proprietary ratios to significantly reduce inflammatory biomarkers associated with psychiatric and neurodegenerative disorders, with a primary focus on PTSD. The leadership team at GoodCap includes experts with extensive experience in pharmaceuticals, biotechnology, and molecular biology, bringing a wealth of knowledge to the company's mission. With a commitment to advancing recovery processes, GoodCap is at the forefront of integrating psychedelic therapies into mainstream healthcare practices. Generated from the website

Wellesley Therapeutics Inc is a pharmacy located in the heart of Toronto, ON. This facility offers a wide range of pharmaceutical services, including medication management, compounding, and health consultations. With a dedicated team of professionals, Wellesley Therapeutics focuses on providing personalized care to meet the unique needs of each patient in the community. Generated from this place's information

Psyence Biomedical Ltd, based in Toronto, is the world's first life science biotechnology company traded on the NASDAQ, focusing on the development of botanical, nature-derived, or non-synthetic psilocybin-based psychedelic medicines. The company is committed to an evidence-based approach to innovation, aiming to create safe and effective psychedelic therapeutics for a broad range of mental health disorders, particularly within the context of palliative care. Led by CEO Dr. Neil Maresky, Psyence operates at the intersection of medicine, commerce, and science, leveraging expertise in intellectual property and capital markets to drive sustainable growth and shareholder value. The company is pioneering the use of natural psychedelics to address mental health challenges, specifically targeting anxiety and depression among patients in palliative care settings. Generated from the website